Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 501–600 of 4,108
Patient physiology influences the MRI-based vertebral bone quality score
Aynaszyan, S., Devia, L. G., Udoeyo, I. F., Badve, S. A., & DelSole, E. M. (2022) · The Spine Journal · doi:10.1016/j.spinee.2022.06.003 · Cited by 58
Moreland, B. L., Legha, J. K., Thomas, K. E., & Burns, E. R. (2022) · Journal of Aging and Health · doi:10.1177/08982643221132450 · Cited by 65
“While the USPSTF found insufficient evidence to make a similar recommendation for men, several expert groups recommend BMD testing for men older than 70, and for younger men aged 50–70 when risk factors are present (Cosman et al., 2014; Watts et al., 2012).”
BackgroundLeBoff, M. S., Yue, A. Y., Copeland, T., Cook, N. R., Buring, J. E., & Manson, J. E. (2015) · Contemporary Clinical Trials · doi:10.1016/j.cct.2015.01.007 · Cited by 50
Self-citationVillar, S. S., Gutiérrez, F., Miralles, C., Berenguer, J., Rivero, A., Martínez, E., & Moreno, S. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw097 · Cited by 60
Utility of DXA for monitoring, technical aspects of DXA BMD measurement and precision testing
CAREY, J. J., & Delaney, M. F. (2017) · Bone · doi:10.1016/j.bone.2017.05.021 · Cited by 59
Chen, X., Zhi, X., Cao, L., Weng, W., Pan, P., Hu, H., Liu, C., Zhao, Q., Zhou, Q., Cui, J., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.394 · Cited by 52
Retractedde Oliveira, L. C., de Oliveira, R. G., & Pires-Oliveira, D. A. D. A. (2018) · Journal of Geriatric Physical Therapy · doi:10.1519/jpt.0000000000000184 · Cited by 54
Baek, Y., Jeon, H., Oh, I., Yang, H., Park, J., & Shin, J. (2019) · Cancer Epidemiology · doi:10.1016/j.canep.2019.05.013 · Cited by 56
Sanfélix‐Genovés, J., Sanfélix‐Gimeno, G., Peiró, S., Hurtado, I., Fluixá, C., Fuertes, A., Campos, J., Giner, V., & Baixauli, C. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2018-6 · Cited by 62
Yang, X., Chang, T., Yuan, Q., Wei, W., Wang, P., Song, X., & Yuan, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.930244 · Cited by 56
“The participants were divided into the following groups based on the diagnostic criteria recommended by the World Health Organization (26) and the results of the DXA measurement: T score ≥ -1, control group; -2.”
MethodInfluentialHealth care costs of osteopenia, osteoporosis, and fragility fractures in Mexico
Carlos, F., Clark, P., Galindo-Suárez, R. M., & Chico‐Barba, G. (2013) · Archives of Osteoporosis · doi:10.1007/s11657-013-0125-4 · Cited by 51
Kuang, W., Zheng, L., Xu, X., Lin, Y., Lin, J., Wu, J., & Tan, J. (2017) · Bone Research · doi:10.1038/boneres.2017.37 · Cited by 49
Schousboe, J. T., Lix, L. M., Morin, S. N., Derkatch, S., Bryanton, M., Alhrbi, M., & Leslie, W. D. (2019) · Bone · doi:10.1016/j.bone.2019.01.009 · Cited by 51
Cost-benefit analysis of calcium and vitamin D supplements
Weaver, C. M., Bischoff-Ferrari, H. A., & Shanahan, C. J. (2019) · Archives of Osteoporosis · doi:10.1007/s11657-019-0589-y · Cited by 55
Telomere length and telomerase activity in osteoporosis and osteoarthritis (Review)
Fragkiadaki, P., Nikitovic, D., Kalliantasi, K., Sarandi, E., Thanasoula, M., Stivaktakis, P. D., Nepka, C., Spandidos, D. A., Theodoros, T., & Tsatsakis, A. M. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.8370 · Cited by 69
Risk Communication and Shared Decision Making in the Care of Patients With Osteoporosis
Lewiecki, E. M. (2010) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2010.06.005 · Cited by 49
Self-citationLöffler, M. T., Sollmann, N., Burian, E., Bayat, A., Aftahy, A. K., Baum, T. H., Meyer, B., Ryang, Y., & Kirschke, J. S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.552719 · Cited by 55
“The National Osteoporosis Foundation (NOF) recommends all postmenopausal women and men age 50 and older should be evaluated for osteoporosis risk in order to determine the need for BMD testing (5).”
BackgroundCarr, A., Grund, B., Neuhaus, J., Schwartz, A. V., Bernardino, J. I., White, D., Badal‐Faesen, S., Avihingsanon, A., Ensrud, K. E., Hoy, J., et al. (2015) · HIV Medicine · doi:10.1111/hiv.12242 · Cited by 46
Shibli-Rahhal, A. A., Vaughan‐Sarrazin, M., Richardson, K. K., & Cram, P. M. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1536-y · Cited by 52
Sayed-Hassan, R. M., Bashour, H. N., & Koudsi, A. (2013) · Archives of Osteoporosis · doi:10.1007/s11657-013-0149-9 · Cited by 53
Fracture prevention service to bridge the osteoporosis care gap
Baroni, M., Zampi, E., Rinonapoli, G., Serra, R., Zengarini, E., Duranti, G., Ercolani, S., Conti, F., Caraffa, A., Mecocci, P., et al. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s76695 · Cited by 60
Osteoporosis Management in Ankylosing Spondylitis
Hinze, A. M., & Louie, G. H. (2016) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-016-0055-6 · Cited by 48
Thai Osteoporosis Foundation (TOPF) position statements on management of osteoporosis
Songpatanasilp, T., Sritara, C., Kitisomprayoonkul, W., Chaiumnuay, S., Nimitphong, H., Charatcharoenwitthaya, N., Pongchaiyakul, C., Namwongphrom, S., Kitumnuaypong, T., Srikam, W., et al. (2016) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2016.10.002 · Cited by 61
Osteoporosis and Fracture Risk Evaluation and Management
Watts, N. B., & Manson, J. E. (2016) · JAMA · doi:10.1001/jama.2016.19087 · Cited by 49
Weycker, D. A., Edelsberg, J., Barron, R., Atwood, M., Oster, G., Crittenden, D. B., & Grauer, A. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4103-3 · Cited by 65
Curtis, J. R., & Silverman, S. L. (2013) · Current Osteoporosis Reports · doi:10.1007/s11914-013-0177-9 · Cited by 48
Ross, B. J., Lee, O. C., Harris, M. B., Dowd, T. C., Savoie, F. H. “., & Sherman, W. F. (2021) · JBJS Open Access · doi:10.2106/jbjs.oa.20.00142 · Cited by 67
Kumar, A., Sood, A., Singhmar, R., Mishra, Y. K., Thakur, V. K., & Han, S. S. (2022) · Biomaterials Science · doi:10.1039/d2bm00894g · Cited by 52
The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial
Czerwinski, E. J., Cardona, J., Plebanski, R., Recknor, C. P., Vokes, T., Saag, K. G., Binkley, N., Lewiecki, E. M., Adachi, J. D., Knychas, D., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4719 · Cited by 55
“Although some recent guidelines have recommended ageand risk-based osteoporosis screening for men,((15-17)) evidence for osteoporosis treatment efficacy in men is limited.”
BackgroundSelf-citationAdvancement in the Treatment of Osteoporosis and the Effects on Bone Healing
Kushchayeva, Y. S., Pestun, I., Kushchayev, S. V., Radzikhovska, N., & Lewiecki, E. M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11247477 · Cited by 54
“The use of serum P1NP and CTX has been recommended by the International Osteoporosis Foundation (IOF), the International Federation of Clinical Chemistry (IFCC) Bone Marker Standards Working Group, and the National Osteoporosis Foundation (NOF) as bone turnover reference markers for fracture risk prediction and for OP…”
BackgroundSelf-citationChronic Kidney Disease with Mineral Bone Disorder and Vascular Calcification: An Overview
Izzo, C., Secondulfo, C., Bilancio, G., Visco, V., Virtuoso, N., Migliarino, S., Ciccarelli, M., Pietro, P. D., Mura, L. L., Damato, A., et al. (2024) · Life · doi:10.3390/life14030418 · Cited by 79
“Osteoporosis, defined as a disease characterized by low bone mass, microarchitecture deterioration of bone tissue, bone fragility, and a consequent increase in fracture risk [47], constitutes one of the main features of CKD MBD.”
BackgroundAbe, Y., Iba, K., Sasaki, K., Chiba, H., Kanaya, K., Kawamata, T., Oda, K., Amizuka, N., Sasaki, M., & Yamashita, T. (2014) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-014-0574-x · Cited by 49
Serum Bicarbonate and Bone Mineral Density in US Adults
Chen, W., Melamed, M. L., & Abramowitz, M. K. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.07.007 · Cited by 52
Khanal, A., Peterson, G. M., Castelino, R. L., & Jose, M. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0261-1 · Cited by 59
Herrera, A., Lobo-Escolar, A., Mateo, J., Gil, J., Ibarz, E., & Gracia, L. (2012) · World Journal of Orthopedics · doi:10.5312/wjo.v3.i12.223 · Cited by 55
Greenspan, S. L., Vujevich, K. T., Brufsky, A., Lembersky, B. C., Londen, G. J. V., Jankowitz, R., Puhalla, S. L., Rastogi, P., & Perera, S. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3100-7 · Cited by 48
Vertebral fracture assessment by new dual-energy X-ray absorptiometry
Bazzocchi, A., Spinnato, P., Fuzzi, F., Diano, D., Morselli‐Labate, A. M., Sassi, C., Salizzoni, E., Battista, G., & Guglielmi, G. (2012) · Bone · doi:10.1016/j.bone.2012.01.018 · Cited by 53
Morizio, P., Burkhart, J. I., & Ozawa, S. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018768808 · Cited by 50
Osteoporosis and Bone Health in Transgender Persons
Stevenson, M. O., & Tangpricha, V. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.02.006 · Cited by 56
Kang, Y.-S., Kim, J.-C., Kim, J., & Kim, S. H. (2019) · PubMed · Cited by 47
Shi, Y., Zhan, Y., Chen, Y., & Jiang, Y. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-020-0694-y · Cited by 53
Nutrients in the Prevention of Osteoporosis in Patients with Inflammatory Bowel Diseases
Ratajczak, A. E., Rychter, A. M., Zawada, A. E., Dobrowolska, A., & Krela‐Kaźmierczak, I. (2020) · Nutrients · doi:10.3390/nu12061702 · Cited by 58
ACOG Clinical Practice Guideline No. 1: Osteoporosis Prevention, Screening, and Diagnosis
(2021) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000004514 · Cited by 64
Crandall, C. J., Merkin, S. S., Seeman, T. E., Greendale, G. A., Binkley, N., & Karlamangla, A. S. (2012) · Bone · doi:10.1016/j.bone.2012.04.009 · Cited by 59
The Treatment of Complementary and Alternative Medicine on Premature Ovarian Failure
Lin, J., Wu, D., Jia, L., Liang, M., Liu, S., Qin, Z., Zhang, J., Han, Y., Liu, S., & Zhang, Y. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/6677767 · Cited by 46
Association of Bone Mineral Density and Dementia: The Rotterdam Study
Xiao, T., Ghatan, S., Mooldijk, S. S., Trajanoska, K., Oei, L., Gomez, M. M., Ikram, M. K., Rivadeneira, F., & Ikram, M. A. (2023) · Neurology · doi:10.1212/wnl.0000000000207220 · Cited by 57
“Previous studies focused solely on BMD, assessed through dual-energy X-ray absorptiometry (DXA) scanning of clinically relevant skeletal sites, that is, femoral neck and lumbar spine.(14) More recently, trabecular bone score (TBS) has been developed, which is a novel gray-level texture measurement connected to bone mi…”
Lo, J. C.-M., Burnett‐Bowie, S. M., & Finkelstein, J. S. (2011) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2011.07.001 · Cited by 66
Choi, E., Choi, K.-H., Park, S. M., Shin, D., Joh, H., & Cho, E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147762 · Cited by 62
Vaziri, F., Dabbaghmanesh, M. H., Samsami, A., Nasiri, S., & Shirazi, P. T. (2016) · Early Human Development · doi:10.1016/j.earlhumdev.2016.07.011 · Cited by 54
Plain vitamin D or active vitamin D in the treatment of osteoporosis: where do we stand today?
Ringe, J. D. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-020-00842-0 · Cited by 52
Nanotechnology for treating osteoporotic vertebral fractures
Yang, L., Gao, C., Wei, D., Yang, H., & Chen, T. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s85037 · Cited by 46
Management of osteoporosis in men on androgen deprivation therapy
Adler, R. A. (2010) · Maturitas · doi:10.1016/j.maturitas.2010.11.003 · Cited by 49
McCloskey, E. V., Harvey, N. C., Johansson, H., & Kanis, J. А. (2016) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000304 · Cited by 53
Darbà, J., Kaskens, L., Pérez‐Álvarez, N., Palacios, S., Neyro, J. L., & Rejas, J. (2015) · BMC Public Health · doi:10.1186/s12889-015-1684-7 · Cited by 46
Polat, B., Halıcı, Z., Çadırcı, E., Albayrak, A., Karakuş, E., Bayır, Y., Bilen, H., Sahin, A., & Yüksel, T. N. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.07.033 · Cited by 45
In Situ Sensor Advancements for Osteoporosis Prevention, Diagnosis, and Treatment
Liu, L., & Webster, T. J. (2016) · Current Osteoporosis Reports · doi:10.1007/s11914-016-0339-7 · Cited by 47
The Effectiveness of Acupuncture for Osteoporosis: A Systematic Review and Meta-Analysis
Pan, H., Jin, R., Li, M., Liu, Z., Xie, Q., & Wang, P. (2018) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x18500258 · Cited by 47
Talevski, J., Sanders, K. M., Duque, G., Connaughton, C., Beauchamp, A., Green, D., Millar, L., & Brennan-Olsen, S. L. (2019) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.02.022 · Cited by 45
Kaempferol promotes bone formation in part via the mTOR signaling pathway
Zhao, J., Wu, J., Xu, B., Yuan, Z., Leng, Y., Min, J., Lan, X., & Luo, J. F. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10747 · Cited by 45
Dielectric characterization of diseased human trabecular bones at microwave frequency
Amin, B., Shahzad, A., Farina, L., Parle, E., McNamara, L. M., O’Halloran, M., & Elahi, A. (2020) · Medical Engineering & Physics · doi:10.1016/j.medengphy.2020.01.014 · Cited by 45
Oxidative balance score and risk of osteoporosis among postmenopausal Iranian women
Shahriarpour, Z., Nasrabadi, B., Zarifi, S. H., Shariati-Bafghi, S.-E., Yousefian-Sanny, M., Karamati, M., & Rashidkhani, B. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-021-00886-w · Cited by 48
Lan, H., Liu, W., Zheng, H., Feng, H., Zhao, W., Hung, W., & Li, H. (2022) · Food & Function · doi:10.1039/d1fo02218k · Cited by 47
Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: 2022 update
Tai, T., Huang, C., Huang, H., Yang, R., Chen, J., Cheng, T., Chen, F., Chen, C., Chang, Y., Hung, W., et al. (2023) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2023.01.007 · Cited by 51
Osteoporosis and jawbones in women
Gülşahı, A. (2015) · Journal of International Society of Preventive and Community Dentistry · doi:10.4103/2231-0762.161753 · Cited by 44
Sex-Specific Issues in Inflammatory Bowel Disease.
Rosenblatt, E. S., & Kane, S. V. (2015) · PubMed · Cited by 48
Monaco, M. D., Castiglioni, C., Toma, E. D., Gardin, L., Giordano, S., Monaco, R. D., & Tappero, R. (2014) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2014.04.003 · Cited by 49
Health beliefs about osteoporosis and osteoporosis screening in older women and men
Nayak, S., Roberts, M. S., Chang, C.-C. H., & Greenspan, S. L. (2010) · Health Education Journal · doi:10.1177/0017896910364570 · Cited by 44
Yang, H. J., Shim, S. G., Ma, B. O., & Kwak, J. Y. (2016) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000535 · Cited by 45
Association between sarcopenia and osteoporosis in chronic liver disease
Hayashi, M., Abe, K., Fujita, M., Okai, K., Takahashi, A., & Ohira, H. (2018) · Hepatology Research · doi:10.1111/hepr.13192 · Cited by 48
Drug-induced bone loss: a major safety concern in Europe
Nguyen, K. D., Bagheri, B., & Bagheri, H. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1524868 · Cited by 52
Using texture analysis of head CT images to differentiate osteoporosis from normal bone density
Kawashima, Y., Fujita, A., Buch, K. A., Li, B., Qureshi, M. M., Chapman, M. N., & Sakai, O. (2019) · European Journal of Radiology · doi:10.1016/j.ejrad.2019.05.009 · Cited by 53
Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment
Park, S. Y., Ahn, S. H., Yoo, J., Chung, Y., Jeon, Y. K., Yoon, B., Kim, H. Y., Lee, S. H., Lee, J., & Hong, S. (2019) · Journal of Bone Metabolism · doi:10.11005/jbm.2019.26.4.213 · Cited by 49
Late‐onset Hypogonadism: Bone health
Rochira, V. (2020) · Andrology · doi:10.1111/andr.12827 · Cited by 50
Total Joint Arthroplasty and Osteoporosis: Looking Beyond the Joint to Bone Health
Wang, Z., Levin, J. E., Amen, T. B., Arzani, A., Manzi, J. E., & Lane, J. M. (2022) · The Journal of Arthroplasty · doi:10.1016/j.arth.2022.04.010 · Cited by 46
Animal modeling in bone research—Should we follow the White Rabbit?
Macedo, A. S., Feitosa, C. C., Kawamoto, F. Y. K., Marinho, P. V. T., Dal‐Bó, Í. D. S., Monteiro, B. F., Prado, L., Bregadioli, T., Diamante, G. A. C., & Ferrigno, C. R. A. (2019) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12083 · Cited by 50
Disparities in osteoporosis treatments
Liu, Z., Weaver, J., de Papp, A., Li, Z., Martin, J. C., Allen, K. S., Hui, S. L., & Imel, E. A. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3249-0 · Cited by 46
The Pathogenesis, Treatment and Prevention of Osteoporosis in Men
Mosekilde, L., Vestergaard, P., & Rejnmark, L. (2012) · Drugs · doi:10.1007/s40265-012-0003-1 · Cited by 53
Olive oil in the prevention and treatment of osteoporosis after artificial menopause
Liu, H., Huang, H., Li, B., Dong, W., Wang, F., Zheng, X., Chen, Q., Wu, B., & Fan, X. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s72006 · Cited by 47
Pregnancy-related osteoporosis and spinal fractures
Yun, K. Y., Han, S. E., Kim, S. C., et al. (2017) · Obstetrics & Gynecology Science · doi:10.5468/ogs.2017.60.1.133 · Cited by 43
Associations of Parity, Breastfeeding, and Fractures in the Women's Health Observational Study
Crandall, C. J., Liu, J., Cauley, J. A., et al. (2017) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000002096 · Cited by 43
HIV and Vertebral Fractures: a Systematic Review and Metanalysis
Ilha, T. A. S. H., Comim, F. V., Copês, R. M., Compston, J. E., & Premaor, M. O. (2018) · Scientific Reports · doi:10.1038/s41598-018-26312-9 · Cited by 49
Choi, S. T., Kwon, S., Jung, J.-Y., Kim, H., Kim, S.-S., Kim, S.-H., Kim, J., Park, J. H., & Suh, C. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7120507 · Cited by 53
Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use
Lyu, H., Zhao, S. S., Yoshida, K., Tedeschi, S. K., Xu, C. Q., Nigwekar, S. U., Leder, B. Z., & Solomon, D. H. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00924 · Cited by 43
Murray, T. E., Williams, D. J., & Lee, M. J. (2017) · Abdominal Radiology · doi:10.1007/s00261-017-1274-5 · Cited by 43
Liu, W., Lee, B., Nagamani, S. C. S., Nicol, L. E., Rauch, F., Rush, E. T., Sutton, V. R., & ORWOLL, E. S. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad035 · Cited by 48
Hughto, J. M. W., Varma, H., Babbs, G., Yee, K., Alpert, A. B., Hughes, L. D., Ellison, J. E., Downing, J. M., & Shireman, T. I. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1102348 · Cited by 50
Sex- and Age-Specific Prevalence of Osteopenia and Osteoporosis: Sampling Survey
Fan, Y., Li, Q., Liu, Y., Miao, J., Zhao, T., Cai, J., Liu, M., Cao, J., Xu, H., Wei, L., et al. (2024) · JMIR Public Health and Surveillance · doi:10.2196/48947 · Cited by 58
“The BMD was grouped into 3 based on the updated World Health Organization–recommended criteria: T-score ≤ –2.5 was defined as osteoporosis, –2.5 to –1.0 was defined as osteopenia, and T-score>–1.0 was defined as normal BMD [23].”
MethodInfluentialRisk Assessment Tools for Osteoporosis Screening in Postmenopausal Women: A Systematic Review
Crandall, C. J. (2015) · Current Osteoporosis Reports · doi:10.1007/s11914-015-0282-z · Cited by 43
Tee, S. (2011) · Archives of Dermatology · doi:10.1001/archdermatol.2011.354 · Cited by 45
Role of zoledronic acid in the prevention and treatment of osteoporosis
Ste‐Marie, L., Rakel, A., Boucher, A., & Ste‐Marie, L. (2011) · Clinical Interventions in Aging · doi:10.2147/cia.s7282 · Cited by 52
Relationship between Weight, Body Mass Index and Bone Mineral Density of Lumbar Spine in Women
Kim, S. J., Yang, W.-G., Cho, E., & Park, E. (2012) · Journal of Bone Metabolism · doi:10.11005/jbm.2012.19.2.95 · Cited by 43
Pisani, P., Greco, A., Conversano, F., Renna, M. D., Casciaro, E., Quarta, L., Costanza, D., Muratore, M., & Casciaro, S. (2016) · Measurement · doi:10.1016/j.measurement.2016.07.033 · Cited by 44
Non-surgical management of acute osteoporotic vertebral compression fracture: A review
Garg, B., Dixit, V., Batra, S., et al. (2017) · Journal of Clinical Orthopaedics and Trauma · doi:10.1016/j.jcot.2017.02.001 · Cited by 42
Mei, K., Schwaiger, B. J., Kopp, F. K., Ehn, S., Gersing, A. S., Kirschke, J. S., Muenzel, D., Fingerle, A. A., Rummeny, E. J., Pfeiffer, F., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17855-4 · Cited by 42
Osteoporosis, densidad mineral ósea y complejo CKD-MBD (I): consideraciones diagnósticas
Bover, J., Ureña, P., Torregrosa, J., Rodríguez-García, M., Castro-Alonso, C., Górriz, J. L., Láiz, A. M., Cigarrán, S., Benito, S., López‐Báez, V., et al. (2018) · Nefrología · doi:10.1016/j.nefro.2017.12.006 · Cited by 49
Shayganfar, A., Khodayi, M., Ebrahimian, S., & Tabrizi, Z. (2019) · British Journal of Radiology · doi:10.1259/bjr.20180774 · Cited by 48
Ensrud, K. E., Kats, A. M., Boyd, C. M., Diem, S. J., Schousboe, J. T., Taylor, B. C., Bauer, D. C., Stone, K. L., & Langsetmo, L. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.0682 · Cited by 47
Cerani, A., Zhou, S., Forgetta, V., Morris, J. A., Trajanoska, K., Rivadeneira, F., Larsson, S. C., Michaëlsson, K., & Richards, J. B. (2019) · BMJ · doi:10.1136/bmj.l4410 · Cited by 49
Moreira, C. A., Ferreira, C. E. D. S., Madeira, M., Silva, B. C. C., Maeda, S. S., Batista, M. C., Bandeira, F. A. F., Borba, V. Z. C., & Lazaretti‐Castro, M. (2020) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000258 · Cited by 149
“Other drugs that decrease 25(OH)D levels include orlistat, ketoconazole, cholestyramine, teriparatide, and PTH (1-84), and patients on chronic use of these medications should have their vitamin D status assessed (1).”
BackgroundBek, J. W., Shochat, C., Clercq, A. D., Saffel, H. D., Boel, A., Metz, J. R., Rodenburg, F. J., Karasik, D., Willaert, A., & Coucke, P. J. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4327 · Cited by 52
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.